PMID- 29507898
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2471-254X (Electronic)
IS  - 2471-254X (Linking)
VI  - 2
IP  - 3
DP  - 2018 Mar
TI  - Role of monocyte chemoattractant protein-1 in liver fibrosis with transient 
      myeloproliferative disorder in down syndrome.
PG  - 230-236
LID - 10.1002/hep4.1150 [doi]
AB  - Liver fibrosis is a common complication associated with transient 
      myeloproliferative disorder (TMD) in Down syndrome (DS). The exact molecular 
      pathogenesis that regulates disease progression is largely unknown. We recently 
      found serum and/or urinary monocyte chemoattractant protein-1 (MCP-1) as a novel 
      biomarker of liver fibrosis. This study was an in vitro analysis to investigate 
      the fibrogenic activity of MCP-1 using the collagen-producing LX-2 human hepatic 
      stellate cell line. We also examined the fibrogenic activity of serum from a male 
      neonate with DS in whom late-onset liver fibrosis developed even after the 
      resolution of TMD. MCP-1 stimulated both cell growth and collagen synthesis of 
      LX-2 in a dose-dependent manner. Patient serum obtained during the active disease 
      phase significantly up-regulated fibrogenic activity, which was suppressed in the 
      presence of MCP-1-blocking antibody. Transient transforming growth factor beta 1 
      stimulation primed LX-2 to induce prolonged hypersecretion of MCP-1 in the 
      culture supernatant and in collagen synthesis, which was suppressed with MCP-1 
      blocking antibody as well. Conclusion: MCP-1 accounts for the prolonged 
      activation of collagen-producing hepatic stellate cells in both a paracrine and 
      autocrine manner, thereby promoting liver fibrosis. Anti-cytokine therapy 
      targeting the fibrogenic cytokines of MCP-1, for example, herbal medicine, could 
      provide a new therapeutic intervention for liver fibrosis associated with TMD in 
      DS. (Hepatology Communications 2018;2:230-236).
FAU - Kobayashi, Kenichiro
AU  - Kobayashi K
AUID- ORCID: 0000-0001-5691-1928
AD  - Department of Pediatrics Hyogo Kenritsu Amagasaki Sogo Iryo Center Amagasaki 
      Japan.
AD  - Department of Pediatric Hematology and Oncology Research Kokuritsu Kenkyu 
      Kaihatsu Hojin Kokuritsu Seiiku Iryo Kenkyu Center Tokyo Japan.
FAU - Yoshioka, Takako
AU  - Yoshioka T
AD  - Department of Pathology Kokuritsu Kenkyu Kaihatsu Hojin Kokuritsu Seiiku Iryo 
      Kenkyu Center Tokyo Japan.
FAU - Miyauchi, Jun
AU  - Miyauchi J
AD  - Department of Pathology and Laboratory MedicineTokyo Shika Daigaku Ichikawa Sogo 
      Byoin Ichikawa Japan.
FAU - Nakazawa, Atsuko
AU  - Nakazawa A
AD  - Department of Pathology Kokuritsu Kenkyu Kaihatsu Hojin Kokuritsu Seiiku Iryo 
      Kenkyu Center Tokyo Japan.
AD  - Department of Clinical Research Saitama Kenritsu Shoni Iryo Center Saitama Japan.
FAU - Kiyokawa, Nobutaka
AU  - Kiyokawa N
AD  - Department of Pediatric Hematology and Oncology Research Kokuritsu Kenkyu 
      Kaihatsu Hojin Kokuritsu Seiiku Iryo Kenkyu Center Tokyo Japan.
FAU - Maihara, Toshiro
AU  - Maihara T
AD  - Department of Pediatrics Hyogo Kenritsu Amagasaki Sogo Iryo Center Amagasaki 
      Japan.
FAU - Usami, Ikuya
AU  - Usami I
AD  - Department of Pediatrics Hyogo Kenritsu Amagasaki Sogo Iryo Center Amagasaki 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20180201
PL  - United States
TA  - Hepatol Commun
JT  - Hepatology communications
JID - 101695860
PMC - PMC5831021
EDAT- 2018/03/07 06:00
MHDA- 2018/03/07 06:01
PMCR- 2018/02/01
CRDT- 2018/03/07 06:00
PHST- 2017/10/13 00:00 [received]
PHST- 2017/12/14 00:00 [revised]
PHST- 2017/12/27 00:00 [accepted]
PHST- 2018/03/07 06:00 [entrez]
PHST- 2018/03/07 06:00 [pubmed]
PHST- 2018/03/07 06:01 [medline]
PHST- 2018/02/01 00:00 [pmc-release]
AID - HEP41150 [pii]
AID - 10.1002/hep4.1150 [doi]
PST - epublish
SO  - Hepatol Commun. 2018 Feb 1;2(3):230-236. doi: 10.1002/hep4.1150. eCollection 2018 
      Mar.